You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Development of eff ective anti-cancer therapy for mutp53expressing<br />
tumours would lower direct and indirect costs by<br />
reduction of surgery and intensive care, reduction of duration<br />
of medical survey, reduction of emotional burden for<br />
patients and their family and faster reintegration of patients<br />
as part of the working economy. In addition, one should<br />
keep in mind that although novel anti-cancer therapies are a<br />
very exciting avenue, millions of cancer patients in Europe<br />
are presently being treated with conventional chemotherapy.<br />
Current chemotherapy has severe adverse eff ects on the<br />
quality of life of the treated patient. The combination of data<br />
from experimental model systems and the cancer patient<br />
mutp53 database might potentially identify groups of<br />
patients who are not suitable for particular types of contemporary<br />
chemotherapy. Better tools to decide which patients<br />
should be treated and which to be left untreated are<br />
extremely important in reducing the suff ering of those<br />
patients who will not benefi t from the currently available<br />
cancer therapy modalities.<br />
Coordinator<br />
Klas Wiman<br />
Karolinska Institutet<br />
Dept. of Oncology-Pathology<br />
<strong>Cancer</strong> Centre Karolinska<br />
Karolinska Hospital<br />
Stockholm, Sweden<br />
klas.wiman@cck.ki.se<br />
Partners<br />
Galina Selivanova<br />
Sten Nilsson<br />
Karolinska Institutet<br />
Dept. of Oncology-Pathology<br />
<strong>Cancer</strong> Center Karolinska<br />
Stockholm, Sweden<br />
Reuven Agami<br />
Hein Te Riele<br />
Division of Tumour Biology<br />
The Netherlands <strong>Cancer</strong> Institute<br />
Amsterdam, The Netherlands<br />
Jiri Bartèk<br />
Institute of <strong>Cancer</strong> Biology<br />
Dept. of Cell Cycle and <strong>Cancer</strong><br />
Copenhagen, Denmark<br />
Giovanni Blandino<br />
Ada Sacchi<br />
Regina Elena <strong>Cancer</strong> Centre<br />
Molecular Oncogenesis Laboratory<br />
Rome, Italy<br />
Anne-Lise Börresen-Dale<br />
Institute for <strong>Cancer</strong> <strong>Research</strong><br />
Dept. of Genetics<br />
Oslo, Norway<br />
Gianni Del Sal<br />
Laboratorio Nazionale CIB<br />
Trieste, Italy<br />
Wolfgang Deppert<br />
Heinrich-Pette Institute<br />
Hamburg, Germany<br />
Moshe Oren<br />
Varda Rotter<br />
Eytan Domany<br />
Zippora Shacked<br />
Weizmann Institute of Science<br />
Rehovot, Israel<br />
Alan Fersht<br />
MRC Centre for Protein Engineering<br />
University of Cambridge<br />
Cambridge, United Kingdom<br />
Pierre Hainaut<br />
International Agency for <strong>Research</strong><br />
on <strong>Cancer</strong> – IARC<br />
Lyon, France<br />
hainaut@iarc.fr<br />
Christoph Huber<br />
Matthias Theobald<br />
Dept. of Hematology and Oncology<br />
Johannes-Gutenberg-University Medical School<br />
Mainz, Germany<br />
Emil Palecek<br />
Institute of Biophysics<br />
Academy of Sciences of the Czech Republic<br />
Brno, Czech Republic<br />
Neeme Tönisson<br />
Asper Biotech<br />
Tartu, Estonia<br />
Thomas Stanislawski<br />
GanyMed Pharmaceuticals AG<br />
Mainz, Germany<br />
Claes Post<br />
Aprea AB<br />
Stockholm, Sweden<br />
Project number<br />
LSHC-CT-2004-502983<br />
EC contribution<br />
€ 8 000 000<br />
Duration<br />
60 months<br />
Starting date<br />
01/02/2004<br />
Instrument<br />
IP<br />
Project website<br />
www.mutp53.com<br />
BIOLOGY 59
Change language